Related Experiment Video
Updated: Jan 12, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
The Relationship Between IL-6 and IL-10 Expression Levels and the Prognosis in B-Cell Non-Hodgkin Lymphoma Patients
Quan Dong1, Wenxin Lin1, Saihui Yu1
1Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, People's Republic of China.
Purpose:
To explore the relationship between the expression of IL-6 and IL-10 in the blood of B-cell non-Hodgkin lymphoma (B-NHL) patients and their survival time and adverse reactions.
Methods:
The study collected and analyzed blood samples from 488 patients with B-NHL treated with rituximab (94 serum samples, 394 plasma samples) as well as plasma samples from 202 healthy subjects, along with relevant clinical information. Expression levels of IL-6 and IL-10 in the blood were measured using enzyme-linked immunosorbent assay (ELISA).
Results:
The expression of IL-6 in the plasma of B-NHL patients was significantly higher than those in healthy subjects (P < 0.001). Patients with low IL-6 expression (serum) had longer Event Free Survival (EFS) compared to those with high IL-6 expression (P = 0.011). Patients with low IL-10 expression (plasma) had longer Progression Free Survival (PFS) (P = 0.009) and EFS (P = 0.027) compared to those with high IL-10 expression. For patients with collected serum samples, non-GCB have shorter PFS (P = 0.027) and EFS (P = 0.03) than GCB patients. The COX proportional hazards regression model results suggest that elevated plasma IL-10 levels (P = 0.008) and advanced stage (P < 0.001) are risk factors for PFS in B-NHL patients.
Conclusion:
The expression of IL-6 and IL-10 in the blood can serve as important biomarkers for predicting the prognosis of rituximab in patients with B-NHL.
